BeOne Medicines AG Reports Positive Phase 3 Results for ZIIHERA in HER2-Positive Gastroesophageal Cancer

Reuters11-17

BeOne Medicines AG Reports Positive Phase 3 Results for ZIIHERA in HER2-Positive Gastroesophageal Cancer

BeOne Medicines AG has announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without the PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The trial demonstrated improvements in progression-free survival $(PFS)$, overall survival $(OS)$, objective response rate $(ORR)$, and duration of response (DOR) in the ZIIHERA plus TEVIMBRA and chemotherapy arm versus the control arm, in both PD-L1 positive and PD-L1 negative subgroups. The safety profile was consistent with previous data and no new safety signals were observed. The results will be submitted for presentation at a major medical meeting in the first quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20251117406992) on November 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584642320?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584642320","market":"nz","top_or_hot":-1,"title":"BeOne Medicines AG Reports Positive Phase 3 Results for ZIIHERA in HER2-Positive Gastroesophageal Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BeOne Medicines AG Reports Positive Phase 3 Results for ZIIHERA in HER2-Positive Gastroesophageal Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BeOne Medicines AG has announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without the PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The trial demonstrated improvements in progression-free survival <a href=\"https://laohu8.com/S/PFS\">$(PFS)$</a>, overall survival <a href=\"https://laohu8.com/S/OS\">$(OS)$</a>, objective response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a>, and duration of response (DOR) in the ZIIHERA plus TEVIMBRA and chemotherapy arm versus the control arm, in both PD-L1 positive and PD-L1 negative subgroups. The safety profile was consistent with previous data and no new safety signals were observed. The results will be submitted for presentation at a major medical meeting in the first quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20251117406992) on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeOne Medicines AG Reports Positive Phase 3 Results for ZIIHERA in HER2-Positive Gastroesophageal Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeOne Medicines AG Reports Positive Phase 3 Results for ZIIHERA in HER2-Positive Gastroesophageal Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-17 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BeOne Medicines AG Reports Positive Phase 3 Results for ZIIHERA in HER2-Positive Gastroesophageal Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BeOne Medicines AG has announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without the PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The trial demonstrated improvements in progression-free survival <a href=\"https://laohu8.com/S/PFS\">$(PFS)$</a>, overall survival <a href=\"https://laohu8.com/S/OS\">$(OS)$</a>, objective response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a>, and duration of response (DOR) in the ZIIHERA plus TEVIMBRA and chemotherapy arm versus the control arm, in both PD-L1 positive and PD-L1 negative subgroups. The safety profile was consistent with previous data and no new safety signals were observed. The results will be submitted for presentation at a major medical meeting in the first quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20251117406992) on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL500nlP:1","article_id":"2584642320","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584642320","pubTimestamp":1763377238,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BeOne Medicines AG has announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA , a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without the PD-1 inhibitor TEVIMBRA , as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma . The trial demonstrated improvements in progression-free survival , overall survival , objective response rate , and duration of response  in the ZIIHERA plus TEVIMBRA and chemotherapy arm versus the control arm, in both PD-L1 positive and PD-L1 negative subgroups. The safety profile was consistent with previous data and no new safety signals were observed. The results will be submitted for presentation at a major medical meeting in the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688235":"百济神州","BK0239":"医药制造"},"translate_title":"BeOne Medicines AG报告ZIIHERA治疗HER2阳性胃食管癌的3期积极结果","themeId":"12b9cc00d05cc390c8f725385f7a4061","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":0.9},"content_text":"BeOne Medicines AG Reports Positive Phase 3 Results for ZIIHERA in HER2-Positive Gastroesophageal Cancer\n    \n\n        BeOne Medicines AG has announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without the PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The trial demonstrated improvements in progression-free survival $(PFS)$, overall survival $(OS)$, objective response rate $(ORR)$, and duration of response (DOR) in the ZIIHERA plus TEVIMBRA and chemotherapy arm versus the control arm, in both PD-L1 positive and PD-L1 negative subgroups. The safety profile was consistent with previous data and no new safety signals were observed. The results will be submitted for presentation at a major medical meeting in the first quarter of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20251117406992) on November 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584642320","isCrawlerRequest":true}